Assessment of pharmacokinetics, safety, and tolerability following twice‐daily administration of molnupiravir for 10 days in healthy participants

• Main Authors: Marian Iwamoto (Author), Kelly E. Duncan (Author), Prachi K. Wickremasingha (Author), Tian Zhao (Author), Maria V. Liberti (Author), Lieselotte Lemoine (Author), Tatjana Decaesteker (Author), Sylvie Rottey (Author), Brian M. Maas (Author), Gillian Gillespie (Author), S. Aubrey Stoch (Author)
• Format: Book
• Published: Wiley, 2023-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Molnupiravir is an orally administered, small‐molecule ribonucleoside prodrug of β‐D‐N4‐hydroxycytidine (NHC) that has demonstrated potent, broad‐spectrum preclinical activity against RNA viruses and has a high barrier to the development of resistance. A double‐blind, placebo‐controlled, ph...